Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  signal transduction inhibitor
Results 1-25 of 2365 for your search:
Start Over
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients with Progressive Meningiomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071401, NCI-2015-00546, NCI-2015-00501, NCT02523014
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B1371012, NCI-2015-00462, 2014-001345-24, NCT02367456
Vismodegib in Treating Patients with Locally Advanced or Recurrent Orbital or Periocular Basal Cell Cancer
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2014.022, NCI-2015-00927, HUM00082579, ML29160, NCT02436408
Pembrolizumab with or without Vismodegib in Treating Skin Basal Cell Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SKIN0031, NCI-2015-01869, 350, NCT02690948
PF-04449913 in Treating Patients with Acute Leukemia or Myelodysplastic Syndromes at High Risk of Relapse after Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-1558, NCI-2013-00824, 12-1558.cc, NCT01841333
Erismodegib and Paclitaxel in Treating Patients with Recurrent Ovarian Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: UAB 1357, NCI-2015-01335, F140214007, NCT02195973
Itraconazole in Preventing Blood Vessel Growth in Patients with Non-small Cell Lung Cancer Undergoing Surgery
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SCCC-01515, NCI-2015-00458, 122014-038, Mod2_STU 122014-038, NCT02357836
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: B1371013, NCI-2014-02538, 2014-000933-21, 2014-001048-40, SMOI, NCT02226172
Sonidegib and Buparlisib in Treating Patients with Advanced or Metastatic Basal Cell Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SKIN0020, NCI-2014-02200, 5136, NCT02303041
TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients with Advanced EGFR Mutation Positive Non-small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PJC-020, NCI-2015-01139, 9910, 9910/PJC-020, NCT02503722
Itraconazole in Treating Patients with Basal Cell Carcinoma
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: J1299, NCI-2014-01255, NA_00077461, NCT02120677
A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Status: Not yet active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: SHH4811g, NCI-2011-00807, NCT01160250
Photodynamic Therapy and Vismodegib in Treating Patients with Multiple Basal Cell Cancers
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 1511201549, NCI-2016-00096, ML28849, NCT02639117
Radiation Therapy and Vismodegib in Treating Patients With Locally Advanced Head and Neck Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CC #122011, NCI-2013-00871, 122011, NCT01835626
Sonidegib and Lenalidomide after Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC128B, NCI-2014-00170, NCT02086552
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients with Localized Esophageal or Gastroesophageal Junction Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0966, NCI-2015-01554, NCT02530437
Topoisomerase I Inhibitor LMP400 and Topoisomerase I Inhibitor LMP776 in Treating Patients with Relapsed Solid Tumors or Lymphomas
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8273, NCI-2011-02515, 100056, CDR0000662682, NCT01245192, P08394, 10-C-0056, NCT01051635
Sonidegib in Treating Patients with Advanced or Metastatic Liver Cancer That Cannot Be Removed by Surgery or Child-Pugh A/B7 Cirrhosis
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLDE225XUS12T, NCI-2014-01762, 131053, HRPP #131053, NCT02151864
Olaparib and mTOR Kinase Inhibitor AZD2014 or AKT Inhibitor AZD5363 in Treating Patients with Recurrent Endometrial, Triple Negative Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0784, NCI-2014-01973, NCT02208375
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: P1446A-05/72/12, NCI-2013-02011, NCT01841463
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NLG2103, NCI-2014-02331, NCT02073123
Akt/ERK Inhibitor ONC201 in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 051403, NCI-2014-01305, NCT02250781
Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LOXO-TRK-14001, NCI-2014-02044, NCT02122913
Start Over